Online inquiry

IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5177MR)

This product GTTS-WQ5177MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5177MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5540MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ508MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ11465MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ5421MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ9287MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ9057MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ2455MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ7243MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP-1302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW